Friday, December 23, 2016

BRIEF-Portola Pharmaceuticals says FDA accepts NDA for priority review for betrixaban

* Portola Pharmaceuticals announces FDA accepts New Drug

Application for priority review and EMA validates marketing

authorization application for oral, Factor Xa inhibitor

anticoagulant betrixaban

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)